Ascendis Pharma A/S vs Campbell Soup Co. — how do they compare? Ascendis Pharma A/S trades at $254.5 (market cap $16.67B), while Campbell Soup Co. trades at $22.71 (market cap $6.78B). The key difference: Ascendis Pharma A/S is far larger — about 2.5× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays a 6.87% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CPB | |
|---|---|---|
Market Cap | $16.67B | $6.78B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $34.03 |
52-Week Low | $189.74 | $20.00 |
Enterprise Value | $17.04B | $13.38B |
Dividend Yield | — | 6.87% |
Trailing returns across standard periods
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →